Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer

Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.

Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.